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IntroductIon Practicing physicians encounter 
thousands of clinical trials concerning their spe-
cialty published each year. At present there are 
>18 million publications indexed in the MEDLINE 
database alone.1 It is estimated that ca. 25,000 
randomized clinical trials are published annually2 
and their total number may even reach 1,000,0003. 
Such a large number of clinical publications re-
quires skillful use of available sources of medical 
evidence by both scientists and physicians in or-
der to choose the most valuable papers, providing 
complete and true answers to formulated ques-
tions. There is little doubt that this group includes 
original articles concerning primary studies. In 
case of therapeutic interventions they are mainly 
randomized clinical trials, although well-designed 
observational studies may also be a valuable con-
tribution to science and clinical practice.4,5
However, there are often several or even more 
than ten clinical trials dealing with the same 
problem. These publications are sometimes het-
erogeneous and drawing any conclusions based 
on such studies must be preceded by a substantial 
analytical work. Such work could hardly be expect-
ed from practicing physicians. Secondary studies, 
such as review articles, meta-analyses, systematic 
reviews and guidelines, are therefore needed. Meta-
analyses and systematic reviews are more and more 
often published in indexed journals. Unfortunately, 
these 2 categories are sometimes confused.
narrative reviews and systematic reviews A sys-
tematic review is a multistage process aimed 
to identify all available and reliable publications 
regarding a specific problem, to evaluate their re-
liability and to compile available data in a quanti-
tative (meta-analysis) or qualitative manner.6 Ac-
tual work is usually preceded by the development 
of a detailed protocol specifying main directions 
and assumptions of the research process.7
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A large number of scientific articles published every year requires from practicing physicians the abil-
ity to choose among them and to use secondary studies, such as guidelines, review articles, meta-
analyses and systematic reviews. The aim of this article was to discuss basic differences between 
meta-analyses and systematic reviews. Meta-analysis is a mathematical method of pooling the 
results of several or more studies; a meta-analysis may be based on a systematic review, but this 
is not always the case. A systematic review is a multistage process aimed at the identification of 
all reliable evidence regarding a specific clinical problem. Systematic reviews make it possible to 
objectively address particular issues according to the current state of clinical knowledge and there-
fore constitute a reliable basis for clinical decision-making. An appropriate systematic review should 
include: 1) a defined clinical question, 2) pre-specified inclusion and exclusion criteria, 3) complex 
search for medical evidence sources according to a search strategy, 4) critical evaluation of reli-
ability of identified clinical trials, 5) qualitative or quantitative data synthesis and 6) evidence based 
conclusions. These simple criteria, formulated by Cook et al. more than 10 years ago, allow to dif-
ferentiate between a reliable systematic review and a “quasi-systematic” one, as well as between 
a reliable meta-analysis based on a systematic review and a potentially misleading meta-analysis 
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reliability was not assessed in the meta-analysis 
by Hanefeld et al.12
Even a more spectacular example of a meta-
analysis not based (in our opinion) on a credi-
ble systematic review was the work by Nissen 
and Wolski, which – due to controversial results 
– immediately gained publicity. The study report-
ed that use of rosiglitazone was associated with 
a statistically significantly increased risk of myo-
cardial infarction (odds ratio [OR]: 1.43, 95% CI: 
1.03–1.98) and increased risk of cardiovascular 
death (OR: 1.64, 95% CI: 0.98–2.74).13
Nearly at the same time a systematic review 
was published by the Cochrane Collaboration, in 
which a tendency to lack of benefits from rosigl-
itazone was found in certain studies; however, 
the differences were not statistically significant 
and meta-analysis was not performed due to sub-
stantial heterogeneity of the results observed in 
the studies.14
In the paper by Nissen and Wolski lack of 
a comprehensive approach to the search in in-
formation sources was one of the limitations most 
widely discussed in the literature.13
The studies included in the meta-analysis were 
characterized by significant heterogeneity with re-
spect to duration of treatment, comparators and 
the study design. Despite those differences statis-
tical methods assuming homogeneity of the stud-
ies were used for the analysis of pooled data, mak-
ing it easier to achieve statistical significance.15
systematic reviews To differentiate between 
a systematic review and a narrative review seve-
ral key criteria (tAbLE 1) formulated >10 years ago 
by Cook et al. need to be met.8 These include: 
1 a clearly formulated clinical question 
2 pre-defined inclusion and exclusion criteria, 
according to which studies are included in the 
review
3 comprehensive search in medical evidence 
sources
4 critical evaluation of included clinical trials 
5 quantitative data synthesis
6 reasoning based on scientific evidence. 
These criteria do not include all important ele-
ments affecting quality of the review; neverthe-
less, they form a base for further, more detailed 
assessment. Evaluating a systematic review one 
should also consider whether it is up-to-date, was 
based on a protocol7 and how the studies were se-
lected and data extracted.
Formulation of a clinical question A clinical ques-
tion should precisely define the objective and 
scope of the analysis. It cannot be too general, 
e.g. “Are long-acting human insulin analogs effi-
cacious?”. A properly formulated clinical question 
should reflect the PICO (population, intervention, 
comparator, outcomes) format.16 The question 
should specify the type of participants, the type 
of the intervention (or exposure) and the most 
important outcomes. Usually this is enough to de-
fine the problem clearly. Sometimes information 
An important issue discussed in this article is 
the distinction between a systematic review and 
a narrative review. This could be done according 
to a set of simple criteria formulated by Cook et 
al.8 However, most problems encountered by us-
ers of secondary studies are associated with me-
ta-analyses. In our opinion, these terms are of-
ten confused.
Meta-analysis is actually a statistical meth-
od used for evaluation of pooled data from at 
least 2 (usually several or up to 20) trials in or-
der to obtain more precise average results.9 From 
this point of view meta-analysis is just a statisti-
cal test, like the t-Student test or the χ2 test for 
a single study. Reliability of a meta-analysis de-
pends not on its statistical use, but – in the first 
place – on the inclusion criteria for primary stud-
ies. Usually it is preceded by a systematic search 
in medical databases, which allows to identify all 
credible original studies fulfilling a set of pre-de-
fined inclusion criteria. If this is the case, conclu-
sions drawn from a meta-analysis may be treat-
ed equally to those drawn from a systematic re-
view, as the results obtained may be considered 
reliable and based on complete and up-to-date 
information.10 Moreover, a systematic review of-
ten includes quantitative data analysis – a meta-
analysis. Nevertheless, sometimes a meta-anal-
ysis is based on several original papers selected 
by the authors in an arbitrary or unknown man-
ner. Such a meta-analysis does not fulfill the cri-
teria for a systematic review and its results do not 
reflect complete medical evidence, but a fragment 
of it, often arbitrarily selected. Results of such re-
view articles and meta-analyses based on them are 
sometimes contrary to the results of systematic 
reviews dealing with the same problem. For ex-
ample, in 2004 a meta-analysis by Hanefeld et al. 
was published11, which indicated a favorable effect 
of acarbose on a reduction in the risk of cardio-
vascular complications in type 2 diabetes mellitus. 
However, that paper was not based on a complete 
systematic review and eventually included only 
7 clinical trials, both published and unpublished, 
the meta-analysis of which indicated reduced risk 
of myocardial infarction (hazard ratio [HR]: 0.36, 
CI 95%: 0.16–0.80) and all cardiovascular events 
(HR: 0.65, CI 95%: 0.48–0.88).
A year later authors cooperating within the 
Cochrane Collaboration developed a systemat-
ic review on the efficacy and safety of acarbose 
in type 2 diabetes mellitus, which did not con-
firm previous optimistic reports and indicated 
that there are no reliable studies evaluating the 
effect of acarbose on the risk of cardiovascu-
lar disorders. The discrepancy between conclu-
sions of both reviews arose from the fact that 
Hanefeld et al. used the results of several un-
published studies, but made no critical evalua-
tion and did not present the results of particu-
lar studies but only pooled data. The authors of 
the Cochrane Collaboration review decided that 
those data should not have been used in the anal-
ysis because they were not published and their 
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safety of metformin in patients with type 2 dia-
betes mellitus restricting the treatment to mono-
therapy may be justified, while defining the up-
per age limit or exclusion of studies, in which pa-
tients suffered from concomitant arterial hyper-
tension, may result in limited applicability of the 
results. Another important stage is a definition of 
the investigated intervention and the selection 
of comparators. In case of therapeutic interven-
tions a dose of the medication (and sometimes 
the route of administration) should be specified. 
Of course, the intervention may be a specific drug 
(e.g. metformin) or a treatment protocol (inten-
sive insulin therapy, continuous subcutaneous 
insulin infusion [CSII] etc.). For applicability of 
a systematic review selection of the comparator is 
important. The investigated intervention should 
be compared with an alternative currently used 
in clinical practice and not just with a placebo or 
a rarely used alternate intervention. In case of 
long-acting human insulin analogs in type 2 dia-
betes mellitus isophane insulin will therefore be 
a natural comparator, while comparison with ul-
tralente insulin (practically not used in Poland) 
will be less important.
In type 1 diabetes mellitus CSII may be consid-
ered an alternative for use of long-acting analogs, 
while in type 2 diabetes mellitus such a compar-
ison would be unjustified. Endpoints constitute 
another element that should be specified in inclu-
sion and exclusion criteria. In the Cochrane Col-
laboration reviews it is recommended to take into 
account all clinically significant endpoints, main-
ly those important in making a decision wheth-
er a specific intervention should be used. How-
ever, it is not necessary to include all endpoints 
reported in studies when their practical signifi-
cance is low or negligible.18 Apparently, studies 
dealing with a clinical question concerning one 
specific selected endpoint, such as the risk of hy-
poglycemia and cardiovascular events in patients 
with diabetes mellitus treated with glyburide as 
compared to other anti-diabetic medications19 or 
the effect of rosiglitazone on the risk of develop-
ment of a malignancy 20, are also useful. The last 
element defined in the inclusion/exclusion crite-
ria is the design of studies included in the system-
atic review. If the objective is to evaluate effica-
cy and safety of a therapeutic intervention, then 
the most credible design (provided that it is prop-
erly applied) is that of a randomized controlled 
trial (RCT); in general, most systematic reviews 
are based on this type of primary studies. Howev-
er, in certain cases it is necessary to resort to ob-
servational studies. Such a situation may occur if 
data from RCTs are insufficient, the objective is 
detailed assessment of safety, or an RCT would 
be objectionable on ethical grounds. Due to lack 
of appropriate randomized trials evaluation of 
the effect of combination therapy with metform-
in and sulphonylurea on the risk of cardiovas-
cular complications could be performed by Rao 
et al.21 only as a meta-analysis of data from ob-
servational studies. Assessment of the effect of 
concerning the comparators and clinical trial de-
sign is also taken into account. Of course, it is im-
portant to make the question as short and con-
cise (leaving details to be specified in the inclu-
sion and exclusion criteria) as possible, but in the 
first place the question must be unambiguous.17 
In the example mentioned above the clinical ques-
tion should therefore be formulated in a more de-
tailed and “answerable” way (if this is of interest 
to us), e.g. “Does use of long-acting human insu-
lin analogs in patients with type 2 diabetes mel-
litus decrease the risk of nocturnal hypoglycemia 
as compared to isophane insulin?” In the same 
way the following question must be considered 
too general: “Are angiotensin converting enzyme 
inhibitors (ACEIs) efficacious?” We should rath-
er make it more detailed in order to reflect a spe-
cific clinical problem. For example, the question 
may be presented as follows: “Do ACEIs used in 
patients with ischemic heart disease contribute 
to decreased risk of myocardial infarction or car-
diac death?” We may also investigate, “whether 
use of ACEIs decreases mortality in patients with 
circulatory failure?”
Inclusion and exclusion criteria The criteria for 
inclusion and exclusion of primary studies into/
out of the review should be defined according 
to a well-formulated clinical question. Their pre-
cise definition should precede the search in med-
ical evidence sources and the selection of studies 
for analysis. Usually this is done during develop-
ment of a protocol, at an initial stage of the work. 
For the Cochrane Collaboration review protocols 
are mandatory and published as electronic doc-
uments. Publication of the protocol makes de-
velopment of the analysis more transparent and 
therefore increases the chance to obtain credible 
and objective results.7
The inclusion criteria should specify a disease 
or condition under consideration and respective 
diagnostic criteria. Additional limits concerning 
specific subpopulations (age, gender, concomitant 
diseases, past myocardial infarction, the metabolic 
syndrome) are possible; however, these should be 
based on biological premises or data from other 
studies. Unjustified restrictions in inclusion cri-
teria should be avoided since the results of such 
a limited review may not reflect clinical practice. 
For example: in a review concerning efficacy and 
tAbLE 1 Differences between a systematic review and a narrative review  
(based on Cook et al.8)
Feature Narrative review Systematic review
question often broad in scope often a focused clinical question
sources  
and search
not usually specified, 
potentially biased
comprehensive sources and 
explicit search strategy




appraisal variable rigorous critical appraisal
synthesis often a qualitative summary quantitative summary
inferences sometimes evidence-based usually evidence-based
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cigarette smoking on development of type 2 di-
abetes mellitus is possible only by means of me-
ta-analysis of observational studies, since – due 
to ethical reasons – no experimental trials could 
be performed.22
comprehensive search in medical evidence sources 
The main objective of a systematic review is identi-
fication of all credible clinical studies dealing with 
a specific problem, defined by the clinical question. 
It is mandatory to perform the search at least in 
the most important electronic medical databas-
es, including MEDLINE, EMBASE and CENTRAL. 
The former 2 are bases of abstracts published in 
the indexed journals. They include a vast major-
ity of significant papers published worldwide, in 
English and in other languages. A characteristic 
feature of these bases is the fact that if a specific 
journal is indexed in a given database, then all ar-
ticles published in it are listed in this base. Howev-
er, sometimes (although rarely) good and credible 
studies are published in less recognized journals, 
indexed neither in MED LINE, nor in EMBASE. 
This gap is filled in part by the CENTRAL data-
base maintained by the Cochrane Collaboration 
– an independent, international, non-profit orga-
nization, whose mission is to provide reliable evi-
dence in order to assist in decision-making – both 
in clinical practice and management of healthcare 
systems. Members of this organization cooper-
ate within dozens of thematic groups, actively 
seeking for well-designed clinical trials in vari-
ous sources of evidence. Identified trials are then 
registered in the CENTRAL database. It is impor-
tant that search is not limited to generally avail-
able Internet databases (MEDLINE, EMBASE), 
but also includes journals not indexed in these 
bases, often published in original languages (oth-
er than English), and conference abstracts. The 
CENTRAL database contains therefore studies 
thoroughly selected from a wide range of sourc-
es. The bases described above constitute a “canon” 
to be searched during development of each sys-
tematic review; however, in certain situations it 
is necessary to search in specific medical databas-
es or use other methods (reviews of references in 
the identified papers, contacts with the authors 
of the identified papers and experts in a specific 
field, and/or the manufacturer of the drug under 
consideration). Medical databases recommend-
ed by guidelines published in 2007 by the Agen-
cy for Health Technology Assessment in Poland 
are listed in tAbLE 2.23 One must remember that it 
is important not only to search through a spe-
cific medical evidence source, but to do it in the 
right way. For instance, when looking for informa-
tion concerning efficacy and safety of insulin de-
temir in type 2 diabetes mellitus, it is not enough 
to write in the generic name. Usually it is neces-
sary to construct more or less complex questions 
using a range of keywords; a set of such questions 
is called a search strategy. In general, its form re-
flects the clinical question, i.e. the PICO format. 
An example of a search strategy is presented in 
tAbLE 3. In summary, searching in databases may 
be considered systematic, if the authors report-
ed which medical databases were searched and 
what keywords were used.
selection of clinical trials identified within a sys-
tematic review Searching through medical evi-
dence sources in a manner described above results 
in identification of a large number of potentially 
tAbLE 3 Search strategy applied in the Pubmed database for identification 









#5 non-insulin-dependent diabetes mellitus  62095
#6 NIDDM  53403
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 334187
#8 intervention detemir    214
#9 insulin detemir    189
#10 levemir    190
#11 #9 OR #10 OR #11    215
#12 methodsa random 172652
#13 randoma 574673
#14 random allocation  62603
#15 randomised-controlled-trial 309981
#16 randomized-controlled-trial 309981
#17 RCT   3203
#18 #12 OR #13 OR #14 OR #15 OR #16 OR 
#17
575404
#19 search results #22 AND #14 AND #21     65
a simplified filter was used for identification of RCTs; complete, comprehensive and 
methodologically checked filters are available from the SIGN (Scottish Intercollegiate 
Guidelines Network) webpage (http://www.sign.ac.uk/methodology/filters.html)
tAbLE 2 Electronic medical databases to be searched for systematic reviews 





other medical databases CINAHL Database
PsycINFO
European Public Assessment Report (EPAR)
Health Canada
Netherlands Pharmacovigilance Centre Lareb
The Uppsala Monitoring Centre
Thompson Micromedex
other sources references of included studies
periodic safety update reports
conference abstracts
registries of clinical trials
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for assessment of randomized trials is the scale 
proposed by Jadad et al. (tAbLE 4)25, that takes into 
account the presence and method of randomiza-
tion, the presence of a double-blind design (and 
the method of blinding) and the completeness of 
observation (the number of patients lost from the 
study). This tool became very popular due to its 
simplicity and was widely used in the past; many 
authors still use this scale. It is also recommended 
in guidelines published by the Agency for Health 
Technology Assessment in Poland.23 However, the 
Jadad scale was developed >30 years ago. These 3 
decades have seen much development in method-
ology of randomized trials, their assessment and 
interpretation. The Jadad scale is therefore often 
inadequate for complete and appropriate evalu-
ation of a study since it does not include a range 
of important elements affecting its credibility. 
The most recent Cochrane Collaboration guide-
lines concerning principles of development of sys-
tematic reviews recommend use of a somewhat 
more complicated tool, which makes it possible 
to take into account blinding with respect to the 
patients, the assessors and the analysts, inten-
tion-to-treat analysis and possible selectivity of 
the results reported.26
Meta-analysis – quantitative analysis of pooled 
data The results of identified studies must be 
presented in such a way as to make it possible 
to answer the formulated clinical question. The 
preferred form of presentation is quantitative 
analysis of pooled data, i.e. meta-analysis. How-
ever, in certain cases meta-analysis may not be 
feasible and descriptive methods (qualitative anal-
ysis) must be used.
Meta-analysis is a quantitative process in which 
data from single studies are pooled. Meta-analy-
sis makes it possible to obtain one average value 
resulting from data from single trials concerning 
a selected endpoint and (as is the purpose of each 
statistic test) to answer the question whether ob-
served differences may be due to pure chance. The 
weight of a given trial (i.e. its effect on the final re-
sult of meta-analysis) depends on the sample size 
and data scatter (precision of the results).
The final result is the difference between the in-
tervention group and the control group expressed 
as a statistical parameter (e.g. relative risk, odds 
ratio, weighted mean difference etc.). Meta-anal-
yses are typically presented in a graphic form 
called a forest plot or a meta-analysis plot. A ver-
tical line in the central part of the plot, common-
ly known as the “zero effect” line, indicates lack of 
differences between the groups (FIGurE 2). Subse-
quent squares represent mean values reported in 
individual studies, while the ends of a respective 
segment indicate the confidence interval limits. 
The size of the square reflects the weight of the 
study (the larger the square, the greater effect of 
the study on final results of the meta-analysis). If 
a horizontal segment placed over a specific square 
crosses the “zero effect” line, then the difference 
between compared interventions is statistically 
useful articles, of which a dozen or less (rarely 
more) will be included in the review. The follow-
ing important stage is an appropriate selection 
of the identified publications according to pre-de-
fined inclusion and exclusion criteria. This is done 
in 2 steps. First, initial selection based on titles 
and abstracts is performed: an article is rejected 
if its title or abstract is sufficient to consider the 
publication useless. The remaining papers under-
go detailed verification based on their full texts. It 
is required that selection is done by at least 2 in-
vestigators working independently in order to de-
crease the risk of an error. In credible systematic 
reviews the whole selection process is presented 
using a special diagram according to Quality of 
Reporting of Meta-analyses (QUOROM), which 
makes it possible to repeat the process and verify 
its correctness.24 An example of such a diagram 
is presented in FIGurE 1.
critical evaluation of clinical trials identified with-
in the systematic review Any conclusions con-
cerning efficacy or safety of a specific interven-
tion must be based on reliable scientific evidence. 
Not all studies identified within a review fulfill ba-
sic credibility criteria; the authors of a review are 
therefore required not only to identify relevant 
studies, but also to assess their quality. If stud-
ies are considered credible, conclusions based on 
their results (concerning efficacy or safety of a giv-
en intervention) may be drawn with confidence, 
while studies with methodological faults must 
be treated more carefully. The appraisal is usual-
ly based on structured scales or questionnaires. 
One of the simplest and most widely used scales 
1011 
rejected based on analysis 
of titles and abstracts
1200 
identified in electronic medi-
cal databases
2 
identified in references  
of the secondary studies
21 
positions included  
in a systematic review
170 
rejected based on analysis of 
full texts due to:
•  design other than RCT  
(n = 110)
•  healthy population (n = 2)
•  population other than type 2 
diabetes mellitus (n = 12)
•  duration of the intervention 
<4 weeks (n = 40)
•  lack of specified endpoints 
(n = 6)
189 
qualified for further analysis 
based on full texts
FIGurE 1 Selection 
of studies according to 
Quality of Reporting 
of Meta-analyses  
(a hypothetic example)
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late complications of diabetes) makes it possible 
to assess how much useful for the patient is the 
benefit observed. In the Diabetes Control and 
Complications Trial (DCCT) a relationship be-
tween HbA1c reduction and development of mi-
croangiopathy was demonstrated; however, dif-
ferences with respect to the HbA1c observed in 
the DCCT study were higher than those present-
ed in the figure – 1–2%.27 It was not demonstrat-
ed whether a reduction of the glycated hemoglo-
bin level by 0.1% was associated with reduced 
risk of complications in diabetes mellitus. On the 
other hand, the relationship between HbA1c and 
long-term complications is linear and therefore 
it might be stipulated that each reduction in the 
HbA1c level is beneficial for the patient.
Meta-analysis is therefore a way of data pro-
cessing using statistical methods (analogically 
to the t-Student test, the χ2 test or analysis of 
variance [ANOVA]) and reliability of a particular 
meta-analysis depends on quality and homogene-
ity of the studies included. The first and most im-
portant question to be considered is completeness 
and reliability of information used. As mentioned 
above, if a meta-analysis was preceded by a reli-
able systematic review and all credible informa-
tion was included, then its results may be consid-
ered reliable and consistent with the current state 
of knowledge. Completeness of information is an 
important, but not the sole determinant of cred-
ibility of a meta-analysis. Prior to pooling the re-
sults the authors of a meta-analysis should con-
sider whether differences between the studies 
with respect to population characteristics, the in-
tervention, the comparator (a control group) or 
methodology of the trial are not too great. Such 
diversity (called also clinical heterogeneity) may 
distort the results to a significant degree. Clini-
cal heterogeneity (being actually arbitrary, med-
ical assessment of similarity between particular 
studies) should be distinguished from statistical 
heterogeneity, being an answer to the question 
insignificant (for a given p value – the threshold 
– and confidence interval). If, however, the whole 
segment lies on one side of the “zero effect” line, 
the difference is statistically significant.
The lowest part of the graph represents the re-
sult of meta-analysis (in the form of a diamond). 
The diagonal between the upper and lower apex of 
the diamond represents the average value, while 
the left and right apex determine confidence in-
terval. Interpretation of clinical significance is the 
same as for a single study: if the diamond crosses 
the “zero effect” line, then the difference is statis-
tically insignificant; if the whole diamond is lo-
cated on either side of the line, then the differ-
ence is statistically significant.
An example of a result of meta-analysis con-
cerning a comparison between insulin aspart 
and human insulin in type 1 diabetes mellitus 
with respect to weighted mean difference in gly-
cated hemoglobin level is presented in FIGurE 2 
(Pankiewicz, Ryś – unpublished data). Detailed 
analysis of this figure allows for the following 
observations:
1 seven studies were taken into account in the 
meta-analysis
2 in 3 studies statistically significant differenc-
es in favor of insulin aspart were demonstrated 
(respective segments are located to the left of the 
“zero effect” line)
3 the results of the remaining 4 studies are sta-
tistically insignificant (respective segments cross 
the “zero effect” line)
4 the result of the meta-analysis is statistically 
significant in favor of insulin aspart (the whole 
diamond is located to the left).
Clinical significance of the observed difference 
requires separate assessment. The result was pre-
sented as glycated hemoglobin (HbA1c) level re-
duction, i.e. a biochemical parameter, not a mea-
sure of direct benefit to the patients. Demonstra-
tion of a relationship between this parameter and 
incidence of clinically important endpoints (e.g. 
Review: DM1
Comparison: 01 Aspart vs. placebo
Outcome: 01 HBA1c level
Study or sub-category N Aspart 
Mean (SD)




Weight % WMD (fixed) 
95% CI
Home 2000 698 7.88 (0.80) 349 8.00 (0.76) 39.32 –0.12 [–0.22, –0.02]
Raskin 2000 596 7.78 (0.98) 286 7.91 (1.01) 19.53 –0.13 [–0.27, 0.01]
Bode 2001  18 6.90 (0.60)  10 7.10 (0.60)  1.81 –0.20 [–0.66, 0.26]
Iwamoto 2001 143 7.36 (1.12)  62 7.60 (1.08)  3.67 –0.24 [–0.57, 0.09]
Tamas 2001 209 8.02 (0.72) 210 8.18 (0.72) 20.43 –0.16 [–0.30, –0.02]
Bode 2002  59 7.30 (0.70)  59 7.65 (0.80)  5.28 –0.35 [–0.62, –0.08]
Heller 2004 143 7.70 (0.80) 143 7.70 (0.90)  9.97  0.00 [–0.20, 0.20]
Total (95% CI) 1866 1119 100.00 –0.14 [–0.20, –0.07]
Test for heterogeneity: χ² = 4.90, df = 6 (p = 0.56), I² = 0%
Test for overall effect: Z = 4.28 (p <0.0001)
Favours aspart Favours human insulin
–0.5–1 0 0.5 1
FIGurE 2 Weighted 
mean difference between 
insulin aspart and human 
insulin in type 1 diabetes 
mellitus 
Abbreviations: DM1 – 
type 1 diabetes mellitus, 
SD – standard deviation, 
WMD – weighted mean 
difference (meta-analy-
ses prepared in Review 
Manager v.4.2.)
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Of equal importance is adequate education of the 
main groups of recipients of those results – phy-
sicians and scientists – in order to enable them 
to evaluate the results received, which was the 
objective of the authors of this article.
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whether differences between the results of par-
ticular studies may be due to chance.
An example of a meta-analysis, in which the 
problem of clinical heterogeneity remains con-
troversial, is (in our opinion) the paper by Nis-
sen and Wolski mentioned above.13 The authors 
pooled the results of all identified trials, in which 
rosiglitazone was used, regardless of population 
characteristics, the comparators and methodol-
ogy of the studies. The studies included in that 
meta-analysis concerned both patients with type 
2 diabetes mellitus and those with prediabetes; 
placebo, insulin and oral medications (adminis-
tered in monotherapy or combination) were used 
as comparators; the trials differed with respect 
to duration of treatment with rosiglitazone and 
methods of endpoint assessment.
What should an author of a meta-analysis do, 
having found that the studies are statistically 
heterogeneous? There is no simple and univer-
sal answer, but the problem must not be ignored. 
Discussing possible solutions exceeds the scope 
of this article. In short, potential factors of het-
erogeneity should be evaluated prior to analysis 
– this may be done using a single or multi factorial 
meta-regression analysis.28
A similar role may be fulfilled by subgroup anal-
ysis, i.e. assessment whether the results in one 
subgroup differ significantly from the results in 
another subgroup. In each situation a statistical 
form of meta-analysis assuming heterogeneity of 
the results between the studies, i.e. a random ef-
fect model, may be considered.
suMMArY Over the last years significant prog-
ress with respect to quality and reliability of sys-
tematic reviews and meta-analyses has been ob-
served. In many countries they became a basis 
of applications for financing health technologies 
from public means and in most cases published 
guidelines are based on systematic reviews of 
available data. Like all research tools, also these 
require professional and appropriate application. 
tAbLE 4 Jadad scale25
Question Answer  
Yes/No
Score Comments of 
the assessor
Was the study described as randomized?
Was the study described as double-blind?
Was information concerning patient lost 
from the study and the follow-up period 
provided?
Should 1 point be added for a correct and 
properly described method of randomiza-
tion?
Should 1 point be added for a correct and 
properly described method of blinding?
Should 1 point be subtracted for an incor-
rect method of randomization?
Should 1 point be subtracted for an incor-
rect method of blinding?
total
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